

# Therapeutic Options in SPINAL MUSCULAR ATROPHY:



The role of newborn screening and monitoring  
after treatment initiation

**WEDNESDAY, DECEMBER 2<sup>nd</sup>**  
7:00 - 8:00 PM EST

## PLANNING COMMITTEE and SPEAKERS



**HUGH MCMILLAN**  
MD, MSc, FRCPC, FAAN

Pediatric Neurologist,  
Children's Hospital of  
Eastern Ontario  
Associate Professor,  
University of Ottawa  
Ottawa, ON



**ALEX MACKENZIE**  
MD, PhD, FRCPC

Distinguished Chair in Rare  
Neurologic Disease Therapeutics  
Senior Scientist, Children's  
Hospital of Eastern Ontario  
Research Institute  
Professor of Pediatrics, Faculty  
of Medicine, University of Ottawa  
Ottawa, ON



**KATHRYN SELBY**  
BSc, MBChB, MRCP, FRCP

Clinical Assistant Professor,  
Department of Pediatrics,  
Faculty of Medicine,  
University of British Columbia  
Vancouver, BC

**[CLICK HERE](#) to REGISTER for  
this Live Virtual Session!**

## LEARNING OBJECTIVES

- Assess the current landscape of spinal muscular atrophy (SMA) newborn screening (NBS) in Canada and beyond while reviewing NBS reporting methods in various jurisdictions
- Understand treatment options for SMA
- Describe the importance of following standard of care guidelines even when a child is receiving a disease-modifying therapy
- Outline the mechanism of action of AAV-based gene replacement therapies and the balance of benefits vs. known and theoretical risks of these therapies

Visit [cnsfederation.org](https://cnsfederation.org) for more information on  
the CNSF 2020 Webinar series.

This webinar is an accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by the Canadian Neurological Sciences Federation for **1.0 credits**. This program was co-developed by the Canadian Neurological Sciences Federation and EOCI Pharmacomm Ltd and was planned to achieve scientific integrity, objectivity and balance. The Webinar was supported by Novartis Pharmaceuticals Canada Inc. who provided an unrestricted grant and in-kind support.

